Novo Nordisk | NVO - Pasivo Circulante





Pasivo Circulante Cambio Fecha
ANI Pharmaceuticals USD 239.51M 38.6M 2026-03
Aurora Cannabis CAD 66.93M 79M 2026-03
Bausch Health Companies USD 4.53B 350M 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Canopy Growth CAD 158.44M 60.15M 2026-03
Corcept Therapeutics USD 149.18M 16.9M 2026-03
Drreddys Laboratories INR 167.57B 165.8B 2026-03
Eli Lilly USD 36.63B 1.41B 2026-03
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
Merck USD 26.94B 1.38B 2026-03
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Novartis USD 31.37B 4.1B 2026-03
Novo Nordisk DKK 225.16B 9.5B 2026-03
Novo Nordisk DKK 32.79B 203.33B 2025-06
Pacira USD 108.79M 11.8M 2026-03
Perrigo USD 997.6M 15.3M 2026-03
Phibro Animal Health USD 281.87M 500K 2026-03
Prestige Brands USD 120.92M 18.63M 2026-03
Sanofi EUR 30.01B 1.66B 2026-03
Supernus Pharmaceuticals USD 373.93M 35.76M 2026-03
Zoetis USD 2.05B 182M 2026-03